Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk

Aspinwall, L., Stump, T., Taber, J., Drummond, D., Kohlmann, W., Champine, M., & Leachman, S. (2018). Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk (1–). Translational Behavioral Medicine. https://doi.org/http://dx.doi.org/10.1093/tbm/ibx011
Aspinwall, Lisa, Tammy Stump, Jennifer Taber, Danielle Drummond, Wendy Kohlmann, Marjan Champine, and Sancy Leachman. 2018. “Genetic Test Reporting of CDKN2A Provides Informational and Motivational Benefits for Managing Melanoma Risk”. Translational Behavioral Medicine. https://doi.org/http://dx.doi.org/10.1093/tbm/ibx011.
Aspinwall, Lisa, et al. Genetic Test Reporting of CDKN2A Provides Informational and Motivational Benefits for Managing Melanoma Risk. Translational Behavioral Medicine, Feb. 2018, https://doi.org/http://dx.doi.org/10.1093/tbm/ibx011.